Company intelligence / Profile preview

Suzhou Guokuang PharmTech

Suzhou, Jiangsu, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Suzhou Guokuang PharmTech has developed at least one small molecule program, GK201, targeting CTLA4 for the treatment of solid tumors. The company has achieved IND approval for this asset. Published research indicates a focus on novel biaryl derivatives that promote CTLA4 degradation by inhibiting its interaction with ligands, suggesting an innovative approach in immune checkpoint inhibition.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Suzhou Guokuang PharmTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Guokuang PharmTech.

Explore the full profile